Cannabinoid CB1 receptor-interacting proteins: novel targets for central nervous system drug discovery?
Article first published online: 31 MAR 2010
© 2010 The Authors. Journal compilation © 2010 The British Pharmacological Society
British Journal of Pharmacology
Special Issue: Themed Issue: Cannabinoids: Guest Editors: Steve Alexander, Ken Mackie and Ruth Ross
Volume 160, Issue 3, pages 454–466, June 2010
How to Cite
Smith, T. H., Sim-Selley, L. J. and Selley, D. E. (2010), Cannabinoid CB1 receptor-interacting proteins: novel targets for central nervous system drug discovery?. British Journal of Pharmacology, 160: 454–466. doi: 10.1111/j.1476-5381.2010.00777.x
- Issue published online: 19 MAY 2010
- Article first published online: 31 MAR 2010
- Received 18 December 2009; revised 12 March 2010; accepted 20 March 2010
The main pharmacological effects of marijuana, as well as synthetic and endogenous cannabinoids, are mediated through G-protein-coupled receptors (GPCRs), including CB1 and CB2 receptors. The CB1 receptor is the major cannabinoid receptor in the central nervous system and has gained increasing interest as a target for drug discovery for treatment of nausea, cachexia, obesity, pain, spasticity, neurodegenerative diseases and mood and substance abuse disorders. Evidence has accumulated to suggest that CB1 receptors, like other GPCRs, interact with and are regulated by several other proteins beyond the established role of heterotrimeric G-proteins. These proteins, which include the GPCR kinases, β-arrestins, GPCR-associated sorting proteins, factor associated with neutral sphingomyelinase, other GPCRs (heterodimerization) and the novel cannabinoid receptor-interacting proteins: CRIP1a/b, are thought to play important roles in the regulation of intracellular trafficking, desensitization, down-regulation, signal transduction and constitutive activity of CB1 receptors. This review examines CB1 receptor-interacting proteins, including heterotrimeric G-proteins, but with particular emphasis on non-G-protein entities, that might comprise the CB1 receptosomal complex. The evidence for direct interaction with CB1 receptors and potential functional roles of these interacting proteins is discussed, as are future directions and challenges in this field with an emphasis on the possibility of eventually targeting these proteins for drug discovery.
This article is part of a themed issue on Cannabinoids. To view the editorial for this themed issue visit http://dx.doi.org/10.1111/j.1476-5381.2010.00831.x